Short Interest Update on Sangamo BioSciences (SGMO)

Sangamo BioSciences (SGMO) : The short interest in Sangamo BioSciences (SGMO) has increased from 8,642,401 to 9,128,730 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 1,399,106 shares are traded daily in the stock and only 7 days are left for the shorts to cover. The short open interest is 13.3% of the total shares in the hands of the public. The shorts in the stock have gone up by 486,329 shares, which is an increase of 5.6% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.

Sangamo BioSciences (NASDAQ:SGMO): The stock opened at $4.38 on Wednesday but the bulls could not build on the opening and the stock topped out at $4.47 for the day. The stock traded down to $4.13 during the day, due to lack of any buying support eventually closed down at $4.13 with a loss of -6.14% for the day. The stock had closed at $4.40 on the previous day. The total traded volume was 1,071,960 shares.


In a related news, Lanphier Edward O Ii, director officer (President & CEO) of Sangamo Biosciences Inc, unloaded 25,000 shares at an average price of $10.43 on July 15, 2015. The total amount of the transaction was worth $260,750, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.